Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00782379
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Allogeneic Transplantation For Severe Osteopetrosis
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00775931
- Locations
- 🇺🇸
University of MInnesota, Fairview, Minneapolis, Minnesota, United States
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 50
- Registration Number
- NCT00740467
- Locations
- 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2008-06-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT00705120
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT00691015
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
- Conditions
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 1
- Registration Number
- NCT00684255
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
- Conditions
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2014-01-23
- Target Recruit Count
- 30
- Registration Number
- NCT00679536
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 12
- Registration Number
- NCT00669890
- Locations
- 🇺🇸
Morgan Stanley Children's Hospital of NYP, New York City, New York, United States
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 15
- Registration Number
- NCT00670410
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, Morgan Stanley Children's Hospital New York Presbyterian, New York, New York, United States
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
- Conditions
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 18
- Registration Number
- NCT00668564
- Locations
- 🇺🇸
University of Minnesota, Fairview, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.